In contrast, our AD therapeutics approach is based on a new translation-regulatory mechanism of AD pathogenesis whereby AD-activated G9a translates select mRNAs into proteins that are widespread in a range of pathological brain processes that mediate Aβ plaque and NFT pathology. This evidence concerns the gene EHMT2 and Alzheimer disease.